Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TriMaxx Coronary Stent placement · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TRIMAXX | EXPERIMENTAL | TRIMAXX Coronary Stent |
| Name | Type | Description |
|---|---|---|
| TriMaxx Coronary Stent placement | DEVICE | Angioplasty with coronary artery stent placement |
Inclusion Criteria: * Eligible for catheter based treatment * Single coronary lesion requiring treatment * Lesion is accessible with stent device * Completes informed consent for participation * Stable condition (no symptoms of heart attack within 72 hours prior to treatment) Exclusion Criteria: ...
TriMaxx Coronary Stent placement is used for treating Coronary Artery Disease. It is an investigational device being studied in a clinical trial to assess its safety and performance in patients with this condition. The stent is placed in coronary arteries to help keep them open and restore blood flow.
TriMaxx Coronary Stent placement is developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker symbol ABT. Abbott is conducting clinical research to evaluate this investigational coronary stent for the treatment of Coronary Artery Disease.
TriMaxx Coronary Stent placement is in Phase 1 clinical development. It is an investigational device and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the device is still in the early stages of clinical evaluation for Coronary Artery Disease.
TriMaxx Coronary Stent placement has one completed clinical trial, identified as NCT00596661, titled "The TRIMAXX Coronary Stent Trial." This Phase 1 study enrolled 100 participants with Coronary Artery Disease at sites in Brazil and Germany. The trial was uncontrolled and not randomized or double-blinded.
TriMaxx Coronary Stent placement is not FDA approved. It is an investigational device currently in Phase 1 clinical development. The completed Phase 1 trial, NCT00596661, evaluated the stent in 100 patients with Coronary Artery Disease, but the device has not yet received marketing authorization.